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Introduction
Biological therapies are increasingly used for the treatment 
of inflammatory conditions in the realms of rheumatology, 
dermatology, and gastroenterology due to their ability to 
target specific cytokines in the inflammatory cascade. More 
recently these compounds have emerged in oncology to 
target cancer cells directly; stimulate the body’s response 
against the cancer cells, or inhibit pathways that promote 
tumour growth. These agents have led to dramatic 
improvements in treating disease, prolonging life and 
improving quality of life. However, targeting the immune 
system with these drugs increases the risk of respiratory 
infections, which are an important cause of morbidity and 
mortality in these patients (1). The spectrum of potential 
pathogens known to cause respiratory infections in these 
individuals has increased, and to identify the subset of 
pathogens that may be the culprits of the infection it is 
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important to know the nature of the underlying immune 
defect. This is of paramount importance for prevention, 
timely diagnosis and successful treatment of patients 
receiving biological therapies (Table 1). It is also important 
to note that it is not solely the choice of an agent that 
predisposes to particular infections. Concomitant factors 
that might increase an individuals’ risk of contracting an 
infection include the underlying disease, comorbid diseases 
(e.g., diabetes mellitus), increased age, and other medical 
treatment (e.g., use of high dose corticosteroids). Exposure 
to opportunistic pathogens is also increased by living 
or travelling in endemic areas, or through occupational 
exposure, contaminated food, soil and water (2,3). Here 
we provide a concise review of established biological 
therapies and their impact on respiratory infection. The 
investigations required for the detection of opportunistic 
respiratory pathogens and their treatment are not discussed 
here as they are discussed in detail elsewhere (2,4). 
Biological therapy in autoimmune and 
inflammatory diseases 
Tumour necrosis factor (TNF) inhibitors
TNF is a pleiotropic pro-inflammatory cytokine central 
to many aspects of the immune response during disease 
and in the host’s response to infection. When present in 
excessive concentrations it is responsible for the destructive 
inflammatory processes that result in bystander tissue 
damage and consequently is a target in the treatment of 
various inflammatory diseases. The pharmacological class of 
TNF inhibitors includes: (I) etanercept, a soluble p75 TNF 
receptor fusion protein; (II) infliximab, a chimeric anti-
TNF antibody; (III) adalimumab, a fully human monoclonal 
anti-TNF antibody; (IV) certolizumab, an antigen-binding 
fragment (Fab’) of a humanized monoclonal antibody 
coupled to polyethylene glycol; and (V) golimumab, human 
anti-TNF-alpha monoclonal antibody. 
TNF stimulates macrophages to produce cytotoxic 
metabolites, thereby increasing phagocytic killing activity. 
Consequently, inhibition of TNF impairs macrophage 
phagocytosis that predisposes to infection. Although the 
mechanism is not clear anti-TNF therapy also results in 
significant neutropenia (5). Overall, this results in the 
inability to eliminate pathogens and increases the risk of 
developing serious infections requiring hospitalisation, 
which is seen with the use of all TNF inhibitors. However, 
it is important to note that in a meta-analysis including 
>50,000 participants conducted in 2011 a statistically 
significant increased risk was demonstrated only for 
certolizumab [odds ratio (OR) 3.51, 95% CI: 1.59–7.79] (6). 
More recently, a 2015 meta-analysis of patients with 
rheumatoid arthritis, who received biologic drugs, found 
that all the classes of TNF inhibitors increased the risk of 
serious infections compared to traditional disease-modifying 
anti-rheumatic drugs (DMARD) (6). The risk was higher 
when high doses were used compared to standard doses 
(OR 1.90, 95% CI: 1.50–2.39 vs. OR 1.31, 95% CI: 1.09–
1.58) (7), suggesting that the risk of infection may be dose 
dependent. Other risk factors which are demonstrated to 
increase the possibility of infection in patients receiving 
TNF inhibitors include age ≥65 years, concomitant use of 
Table 1 Potential respiratory pathogens according to immune defect
Immune defect Potential respiratory pathogens
Neutropenia/impaired 
neutrophil chemotaxis
Gram positive bacteria (e.g., Staphylococcus aureus, Streptococcus pneumoniae, Nocardia species)
Gram negative bacteria (e.g., Klebsiella pneumoniae)
Fungi (e.g., Aspergillus species, Candida species)
T-cell mediated immunity Herpesviruses (e.g., herpes simplex virus, Cytomegalovirus)
Respiratory viruses (e.g., influenza)
Fungi (e.g., Pneumocystis jirovecii, Histoplasma capsulatum, Cryptococcus neoformans)
Mycobacteria
Nocardia species
Legionella pneumophila
B-cell mediated immunity Encapsulated bacteria (e.g., Streptococcus pneumoniae, Haemophilus influenzae)
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immunosuppressants and co-morbidities such as chronic 
obstructive pulmonary disease (8). Furthermore, the risk 
of infection is deemed highest when starting the TNF 
inhibitor (9). The British Society for Rheumatology 
Biologics Register reported that the risk of infection is 4.6 
(95% CI: 1.8–11.9) times greater in the first 90 days (10), 
highlighting that during this initial period of therapy 
caution is required in patients developing symptoms and 
signs of infection. 
In the first randomised controlled trial of Infliximab, 
one pat ient  developed tuberculos i s  and another 
coccidioidomycosis (11). Since then there has been 
increased recognition of the association between the use of 
TNF inhibitors and the development of active infection, 
especially with opportunistic pathogens (3). Notably, due 
to loss of cellular and humoral immunity with anti-TNF 
therapy, individuals are also predisposed to infections 
with pathogens that normally cause infection in healthy 
individuals such as the respiratory viruses and Streptococcus 
pneumoniae, and in these cases, the ongoing use of TNF 
inhibitors can result in invasive infection. Likewise, TNF 
inhibitors increase the risk of infection with Legionella 
pneumophila, with a relative risk of Legionnaire’s disease 
in rheumatoid arthritis patients treated with anti-TNF 
inhibitors estimated to be between 17 to 21 in comparison 
with the overall risk in France (12).
Of the respiratory infections associated with anti-TNF 
therapy infection with Mycobacterium tuberculosis is the most 
notable, with a 25-fold increased risk of reactivating latent 
M. tuberculosis following initiation of treatment (13). The 
risk is increased because TNF together with IFN-γ plays 
a major role in elimination of mycobacteria and confines 
mycobacteria to granulomas, which keeps the disease in a 
latent state (14). The risk of reactivation is greater with the 
use of infliximab and adalimumab compared to etanercept 
(15,16). Furthermore, anti-TNF therapy increases the risk 
of non-tuberculous mycobacterial infections, including M. 
avium complex, M. chelonae, M. marinum and M. abscessus (14). 
Therefore, current recommendation is to screen individuals 
for active and latent M. tuberculosis infection by taking 
a detailed history, performing a physical examination, 
obtaining an interferon gamma release assay (IGRA) and/or 
tuberculin skin test (TST), and a chest radiograph in those 
with a positive TST/IGRA or if symptoms suggest active 
disease. In most cases, an IGRA is sufficient for screening, 
but in individuals with significant risk factors for previous 
tuberculosis exposure, the TST should also be carried out if 
the initial IGRA is negative. If latent tuberculosis infection 
is diagnosed then treatment should be commenced before 
initiating anti-TNF therapy (17).
TNF also plays a key role in the containment of other 
granulomatous infections including fungal infections, 
particularly in endemic areas, where fungal infections are a 
recognised complication of treatment with TNF inhibitors, 
particularly with infliximab (18,19). Of concern is that 
many cases of pulmonary and disseminated histoplasmosis, 
coccidioidomycosis and blastomycosis are missed in 
these individuals and treatment initiation is delayed, 
which can result in poor outcomes (20). A high index of 
suspicion is required in the presence of dyspnoea, fever, 
and malaise, as well as radiological features of interstitial 
pneumonitis, mediastinal granulomatous lymphadenitis and 
mediastinal fibrosing mediastinitis (21). In endemic areas 
for coccidioidomycosis, despite most infections occurring de 
novo, it is best to perform a chest radiograph and coccidioidal 
serologic tests prior to the initiation of TNF inhibitors 
as re-activation of latent infection can occur (19). Due to 
neutropenia associated with TNF inhibitors, infections with 
Aspergillus species (e.g., A. fumigatus), which are ubiquitous 
environmental fungi, are also of concern particularly in the 
presence of other immunosuppressants (22). Pneumocystis 
jirovecii pneumonia is also reported in individuals receiving 
infliximab, especially within the first month of receiving the 
infusion (23) and when used concomitantly with high doses 
of glucocorticoids (24). Consequently, patients receiving 
both high dose corticosteroids and TNF-inhibitor should 
be considered for PCP prophylaxis.
TNF also plays a key role in the immune response 
against viral infections, and respiratory infections with 
respiratory viruses (respiratory syncytial virus, parainfluenza, 
influenza, adenovirus, metapneumovirus, coronavirus and 
rhinovirus) are relatively common in individuals treated 
with TNF-inhibitors. Re-activation of latent infections with 
viruses from the Herpesviridae family (e.g., human herpes 
virus, cytomegalovirus, and Epstein-Barr virus) are not 
frequently seen, but a high index of suspicion for these is 
required. In immunocompromised individuals, these viral 
infections can be severe and fatal if not identified early so 
that TNF inhibitor therapy can be withheld and anti-viral 
treatment commenced (3,25).
Rituximab
Rituximab is a chimeric/humanised monoclonal antibody 
that acts on CD20+ cells and leads to B cell depletion via 
apoptosis and complement activation before these cells 
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develop into plasma cells (26-28). In addition to B-cell 
depletion, rituximab results in hypogammaglobulinemia, 
which predisposes to recurrent respiratory infection and 
may require treatment with intravenous immunoglobulin 
replacement therapy (29). It is, therefore, crucial to 
obtain baseline serum immunoglobulin levels (IgG, IgA, 
and IgM) prior to initiation of rituximab therapy and 
periodic monitoring to identify persistent immunoglobulin 
deficiencies before the onset of severe infections. In a 
large study of rheumatoid arthritis patients that received 
rituximab, serious infections were encountered in 7% 
of individuals with most having pneumonia, especially 
when low IgM levels were encountered (30). With the 
immunoglobulin deficiency, patients receiving rituximab 
will not mount adequate responses to vaccines, particularly 
polysaccharide vaccines such as that against S. pneumoniae. 
Therefore, to prevent against pneumococcal pneumonia in 
this high-risk group the pneumococcal vaccine should be 
administered before initiation of rituximab treatment. 
Unlike with TNF inhibitors there is no need to 
screen individuals for M. tuberculosis infection, but it is 
important to bear in mind that the risk of re-activation 
of latent tuberculosis infection is heightened when used 
concomitantly with other immunosuppressive agents such 
as high dose corticosteroids (31). 
Belimumab 
B-lymphocyte stimulator (BLyS) is a transmembrane protein 
which is a B-cell activating factor and therefore promotes 
maturation of B-cells into plasma cells and the production 
of antibodies (32). Belimumab is a human monoclonal 
antibody that binds to soluble human B-lymphocyte 
stimulator protein (BLyss) to inhibit its biologic activity in 
patients with systemic lupus erythematosus (SLE) (33). It 
increases the development of serious respiratory infections 
during the first year of treatment, with particular reports 
of coccidioidomycosis and cytomegalovirus pneumonia. 
However, in a randomised clinical trial patients treated with 
belimumab did not have rates of serious infection greater 
than those treated with placebo (34). 
Tocilizumab
Tocilizumab is a humanised monoclonal antibody targeting 
the interleukin (IL)-6 receptor and blocks the downstream 
signalling effects of IL-6 on the function of neutrophils, T 
cells, B cells, and monocytes. Additionally, IL-6 is a potent 
inducer of the hepatic acute phase response and secretion 
of c-reactive protein and is an endogenous pyrogenic (35). 
Therefore, inhibition of IL-6 may predispose to the 
development of severe infection in the absence of a 
febrile and pro-inflammatory response, which may lead to 
diagnostic and therapeutic delays. Tocilizumab can lead 
to neutropenia, but the adverse effect is usually transient. 
However, there remains an increased risk of respiratory 
infection comparable to that seen with TNF inhibitors and 
there is a requirement to screen for latent mycobacterium 
tuberculosis infection prior to initiation of treatment (36). The 
risk is particularly increased in those >65 years of age, with 
underlying co-morbid respiratory disease, on >5 mg/day 
corticosteroids, or on a concomitant DMARD (34-37).
Abatacept
Abatacept is a soluble fusion protein of human IgG1 to 
CTLA4, which is a T-cell surface receptor. The CTLA4 
binds to the B cell thus preventing B cell activation, and T 
cell mediated cytokine release (38). Respiratory infections 
with opportunistic pathogens were reported with abatacept 
therapy (9) but overall the available data do not suggest a 
significantly increased risk of serious infections compared 
to placebo. The risk for reactivation of M. tuberculosis 
associated with abatacept therapy is currently unclear, but 
the manufacturer recommends screening for latent infection 
before treatment initiation (9,32).
Tofacitinib
Tofacitinib is a Janus kinase (JAK) inhibitor that influences 
multiple downstream signalling pathways. The risk of 
infections with tofacitinib is similar to that of DMARDs. 
However, the rate of serious infections with tofacitinib 
is 3/100 patient years and increases in advanced age, 
those with diabetes mellitus and with concomitant use of 
corticosteroids (39). The greatest risk with tofacitinib appears 
to be with infection with herpes zoster and vaccination is 
recommended prior to initiation of treatment (40).
Eculizumab
Eculizumab is a humanized monoclonal antibody that 
binds to the C5 component of complement, inhibiting 
terminal complement activation (32,41). Eculizumab 
increases the risk of life-threatening neisserial infections, 
including N. meningitidis and the manufacturers prescribing 
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information includes a boxed warning describing the risk, 
the need for meningococcal vaccination at least two weeks 
prior to treatment, and the importance of monitoring for 
meningococcal infection (42). Since Eculizumab inhibits 
complement activation it will also increase the risk of 
respiratory infection with other encapsulated pathogens 
such as S. pneumoniae and H. influenzae (43). 
Anakinra
The IL-1 receptor antagonist (IL-1Ra) is a naturally 
occurring glycoprotein inhibitor of IL-1 by binding to the 
IL-1 receptor and anakinra is the recombinant human IL-
1Ra that functions through competitive binding to the IL-1 
receptor (44). The risk of serious infections with anakinra is 
significantly increased compared to placebo with an OR 4.05 
(95% CI: 1.22–16.8) (6). This increases with combination 
etanercept, and therefore the use of anakinra in combination 
with other biological therapies is not recommended (45). 
Regarding the reactivation of latent M. tuberculosis there is 
one case report in the literature (46) and overall the data 
does not suggest that anakinra significantly increases the 
risk of developing tuberculosis (6). 
Ustekinumab
Ustekinumab is a human IgG1 kappa monoclonal antibody 
that binds to the shared p40 subunit of IL-12 and IL-
23, preventing the binding of the pro-inflammatory 
cytokines IL-12 and IL-23 to their cell surface receptor. 
It results primarily in impairment of natural killer (NK) 
cell activation, as well as CD4+ T-cell differentiation and 
activation. Moreover, it interferes with the expression of 
monocyte chemotactic protein (MCP)-1, TNF, interferon-
inducible protein-10 (IP-10), and IL-8. Due to the 
significant effect on pro-inflammatory cytokine signalling 
and impairment of adaptive immunity, there is concern 
that ustekinumab may increase the risk for infections, but 
to date, the available data is limited to case reports (47) 
and current studies have not demonstrated a significantly 
increased risk of pneumonia. However, the incidence of 
nasopharyngeal infections is increased by up to 10% (48). 
As many trials of ustekinumab were in individuals previously 
screened for latent M. tuberculosis infection, there is no 
demonstrable increased risk of tuberculosis reactivation, and 
the manufacturer continues to recommend that patients are 
screened for latent M, tuberculosis infection before initiation 
of treatment (49).
Biological therapy in cancer
Biological therapies, also known in this context as 
immunotherapies, have emerged as game changers in the 
treatment of various types of cancer (e.g., haematological, 
skin, gastric, breast, renal, urothelial and lung malignancies). 
Although many of these drugs are new, others have long 
been established in the treatment of cancer; For example, 
the FDA approved Bacillus Calmette-Guérin (BCG) in 
1990 for the intravesical treatment of bladder cancer. 
These therapies mainly aim to alter the host’s immune 
response so that it can detect and eliminate the cancer 
cells or inhibit tumour growth. Immunotherapies largely 
consist of (I) monoclonal antibodies that target antigens 
on the cell surface enabling the immune system to destroy 
them (e.g., alemtuzumab); (II) monoclonal antibodies that 
that inhibit checkpoint molecules to prevent cancer cells 
from evading the immune system (e.g., nivolumab); (III) 
monoclonal antibodies that inhibit cancer growth factors 
(e.g., bevacizumab); (IV) immunoconjugates containing 
antibodies that target specific antigens and deliver cytotoxic 
or radioactive substances (e.g., ado-trastuzumab emtansine); 
(V) cytokines that stimulate the immune system and induce 
cell apoptosis (e.g., interferons); and (VI) cancer vaccines 
that contain cancer-associated antigens to stimulate T-cells 
to kill cancer cells (e.g., sipuleucel-T). 
The most notable adverse effects from immunotherapy 
are due to stimulation of the immune response, and 
these may mimic infection by causing flu-like symptoms 
and breathlessness due to pneumonitis. In a study of 
patients receiving checkpoint inhibitors, the incidence 
of pneumonitis was 5–10% with the highest frequency 
seen in those receiving combination treatment with anti-
PD1 and anti-CTLA4 inhibitors (50). In these cases, 
infectious aetiologies need to be excluded before initiation 
of treatment. The management of immune-related adverse 
events is with immunosuppressants (e.g., high dose 
corticosteroids, mycophenolate mofetil or TNF inhibitors) 
and these drugs will increase the risk of subsequent 
respiratory infection in particular with pathogens such as M. 
tuberculosis, P. jirovecii, A. fumigatus and the herpes viruses 
(2,4,51,52). In a study of 740 patients receiving checkpoint 
inhibitors for the treatment of melanoma bacterial 
pneumonia, P. jirovecii pneumonia and invasive pulmonary 
aspergillosis were identified in 1.8%, 0.4% and 0.3% of 
patients respectively (53), suggesting that although rare, a 
high index of suspicion is required to identify these culprit 
pathogens. Like the PD-1 inhibitors, the PD-L1 inhibitors 
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(e.g., atezolizumab, avelumab) are also associated with 
pneumonitis and development of severe respiratory infection 
in up to 5% of patients (54,55). Other commonly used 
biologicals that are reported to increase the risk of respiratory 
infections include the monoclonal antibodies targeting CD20 
(e.g., rituximab, ofatumumab, obinutuzumab, tositumomab, 
ibritumomab tiuxetan), that lead to B-cell depletion and 
toxicity causing neutropenia (56-58), monoclonal antibodies 
targeting CD52 (e.g., alemtuzumab) that cause B-cell lysis, 
T-cell depletion and neutropenia (59), and monoclonal 
antibodies targeting CD33 (e.g., gemtuzumab) that results 
in myelosuppression (60). Use of the cytokine IL-2 
(aldesleukin) is also associated with an increased risk of 
respiratory infections due to neutrophil dysfunction (61). 
Importantly, the risk of respiratory infections with biological 
agents in the treatment of cancer is further augmented 
by their use in combination with immunosuppressive 
chemotherapeutic agents that frequently result in cytopenia.
Most of these infections can be prevented with 
prophylactic medication, but the frequency currently 
remains too low to justify their routine use and further 
research using larger cohorts are needed to demonstrate 
their cost-effectiveness. It is also important to note that 
discontinuation of the biological agent may not lead to rapid 
cessation of immunosuppression due to the long half-life of 
most monoclonal antibodies. Furthermore, in the presence 
of active infection discontinuation of immunosuppressive 
agents may lead to paradoxical worsening as the recovering 
immune system reacts to the pathogen, as seen in immune 
reconstitution inflammatory syndrome seen in the treatment 
of human immunodeficiency virus infection. 
Conclusions
Biological therapies represent a revolution in the treatment 
of chronic inflammatory diseases and cancer, especially in 
cases refractory to conventional treatment modalities. They 
offer significant benefits in disease control and improving 
quality of life. As with all immunosuppressant agents, it is 
important to be aware and vigilant for signs of infection, 
as these therapies confer a significantly increased risk of 
respiratory infections.
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